Top

Published in:

Open Access 01-12-2024 | Hepatocellular Carcinoma | Review

Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion

Authors: Junli Lu, Yiming Luo, Dean Rao, Tiantian Wang, Zhen Lei, Xiaoping Chen, Bixiang Zhang, Yiwei Li, Bifeng Liu, Limin Xia, Wenjie Huang

Published in: Experimental Hematology & Oncology | Issue 1/2024

Abstract

Paradoxically, tumor development and progression can be inhibited and promoted by the immune system. After three stages of immune editing, namely, elimination, homeostasis and escape, tumor cells are no longer restricted by immune surveillance and thus develop into clinical tumors. The mechanisms of immune escape include abnormalities in antitumor-associated immune cells, selection for immune resistance to tumor cells, impaired transport of T cells, and the formation of an immunosuppressive tumor microenvironment. A population of distinct immature myeloid cells, myeloid-derived suppressor cells (MDSCs), mediate immune escape primarily by exerting immunosuppressive effects and participating in the constitution of an immunosuppressive microtumor environment. Clinical trials have found that the levels of MDSCs in the peripheral blood of cancer patients are strongly correlated with tumor stage, metastasis and prognosis. Moreover, animal experiments have confirmed that elimination of MDSCs inhibits tumor growth and metastasis to some extent. Therefore, MDSCs may become the target of immunotherapy for many cancers, and eliminating MDSCs can help improve the response rate to cancer treatment and patient survival. However, a clear definition of MDSCs and the specific mechanism involved in immune escape are lacking. In this paper, we review the role of the MDSCs population in tumor development and the mechanisms involved in immune escape in different tumor contexts. In addition, we discuss the use of these cells as targets for tumor immunotherapy. This review not only contributes to a systematic and comprehensive understanding of the essential role of MDSCs in immune system reactions against tumors but also provides information to guide the development of cancer therapies targeting MDSCs.

Gabrilovich DI, Bronte V, Chen SH, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007;67(1):425. https://doi.org/10.1158/0008-5472.CrossRefPubMedPubMedCentral

Bennett JA, Rao VS, Mitchell MS. Systemic bacillus Calmette-Guerin (BCG) activates natural suppressor cells. Proc Natl Acad Sci U S A. 1978;75(10):5142–4. https://doi.org/10.1073/pnas.75.10.5142.CrossRefPubMedPubMedCentral

Bronte V, Brandau S, Chen SH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150. https://doi.org/10.1038/ncomms12150.CrossRefPubMedPubMedCentral

Cassetta L, Baekkevold ES, Brandau S, et al. Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. Cancer Immunol Immunother. 2019;68(4):687–97. https://doi.org/10.1007/s00262-019-02302-2.CrossRefPubMedPubMedCentral

Park JA, Wang L, Cheung NV. Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response. J Hematol Oncol. 2021;14(1):142. https://doi.org/10.1186/s13045-021-01156-5.CrossRefPubMedPubMedCentral

Bronte V, Serafini P, De Santo C, et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol. 2003;170(1):270–8. https://doi.org/10.4049/jimmunol.170.1.270.CrossRefPubMed

Kusmartsev S, Nefedova Y, Yoder D, et al. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172(2):989–99. https://doi.org/10.4049/jimmunol.172.2.989.CrossRefPubMed

Mazzoni A, Bronte V, Visintin A, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol. 2002;168(2):689–95. https://doi.org/10.4049/jimmunol.168.2.689.CrossRefPubMed

Groth C, Hu X, Weber R, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120(1):16–25. https://doi.org/10.1038/s41416-018-0333-1.CrossRefPubMed

10.

Kujawski M, Kortylewski M, Lee H, et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest. 2008;118(10):3367–77. https://doi.org/10.1172/JCI35213.CrossRefPubMedPubMedCentral

11.

Murdoch C, Muthana M, Coffelt SB, et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8(8):618–31. https://doi.org/10.1038/nrc2444.CrossRefPubMed

12.

Wang D, Sun H, Wei J, et al. CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. 2017;77(13):3655–65. https://doi.org/10.1158/0008-5472.CAN-16-3199.CrossRefPubMedPubMedCentral

13.

Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70. https://doi.org/10.1126/science.1203486.CrossRefPubMed

14.

Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(4):934–49. https://doi.org/10.1016/j.cell.2017.09.028.CrossRefPubMedPubMedCentral

15.

Tang S, Ning Q, Yang L, et al. Mechanisms of immune escape in the cancer immune cycle. Int Immunopharmacol. 2020;86: 106700. https://doi.org/10.1016/j.intimp.2020.106700.CrossRefPubMed

16.

Fu T, Dai LJ, Wu SY, et al. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol. 2021;14(1):98. https://doi.org/10.1186/s13045-021-01103-4.CrossRefPubMedPubMedCentral

17.

de Coana YP, Wolodarski M, Poschke I, et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget. 2017;8(13):21539–53. https://doi.org/10.18632/oncotarget.15368.CrossRefPubMedPubMedCentral

18.

Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135(1):234–43. https://doi.org/10.1053/j.gastro.2008.03.020.CrossRefPubMed

19.

Casbon AJ, Reynaud D, Park C, et al. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc Natl Acad Sci U S A. 2015;112(6):E566–75. https://doi.org/10.1073/pnas.1424927112.CrossRefPubMedPubMedCentral

20.

Idorn M, Kollgaard T, Kongsted P, et al. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother. 2014;63(11):1177–87. https://doi.org/10.1007/s00262-014-1591-2.CrossRefPubMed

21.

Henick BS, Villarroel-Espindola F, Datar I, et al. Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer. J Immunother Cancer. 2022;10:7. https://doi.org/10.1136/jitc-2022-005025.CrossRef

22.

Okla K, Wertel I, Wawruszak A, et al. Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells - is a new era coming? Crit Rev Clin Lab Sci. 2018;55(6):376–407. https://doi.org/10.1080/10408363.2018.1477729.CrossRefPubMed

23.

Yanez A, Ng MY, Hassanzadeh-Kiabi N, et al. IRF8 acts in lineage-committed rather than oligopotent progenitors to control neutrophil vs monocyte production. Blood. 2015;125(9):1452–9. https://doi.org/10.1182/blood-2014-09-600833.CrossRefPubMed

24.

Condamine T, Mastio J, Gabrilovich DI. Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol. 2015;98(6):913–22. https://doi.org/10.1189/jlb.4RI0515-204R.CrossRefPubMedPubMedCentral

25.

Karin N. The development and homing of myeloid-derived suppressor cells: from a two-stage model to a multistep narrative. Front Immunol. 2020;11: 557586. https://doi.org/10.3389/fimmu.2020.557586.CrossRefPubMedPubMedCentral

26.

Wu Y, Yi M, Niu M, et al. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21(1):184. https://doi.org/10.1186/s12943-022-01657-y.CrossRefPubMedPubMedCentral

27.

Pal S, Dey D, Chakraborty BC, et al. Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV-specific T-cell response and homing. Hepatology. 2022;76(3):759–74. https://doi.org/10.1002/hep.32331.CrossRefPubMed

28.

Hanson EM, Clements VK, Sinha P, et al. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol. 2009;183(2):937–44. https://doi.org/10.4049/jimmunol.0804253.CrossRefPubMed

29.

Parker KH, Sinha P, Horn LA, et al. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res. 2014;74(20):5723–33. https://doi.org/10.1158/0008-5472.CAN-13-2347.CrossRefPubMedPubMedCentral

30.

Ku AW, Muhitch JB, Powers CA, et al. Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. Elife. 2016;510:17875.

31.

Liu Y, Wei J, Guo G, et al. Norepinephrine-induced myeloid-derived suppressor cells block T-cell responses via generation of reactive oxygen species. Immunopharmacol Immunotoxicol. 2015;37(4):359–65. https://doi.org/10.3109/08923973.2015.1059442.CrossRefPubMed

32.

Kusmartsev S, Eruslanov E, Kubler H, et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 2008;181(1):346–53. https://doi.org/10.4049/jimmunol.181.1.346.CrossRefPubMed

33.

Huang Y, Chen X, Dikov MM, et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood. 2007;110(2):624–31. https://doi.org/10.1182/blood-2007-01-065714.CrossRefPubMedPubMedCentral

34.

Niu M, Yi M, Wu Y, et al. Synergistic efficacy of simultaneous anti-TGF-beta/VEGF bispecific antibody and PD-1 blockade in cancer therapy. J Hematol Oncol. 2023;16(1):94. https://doi.org/10.1186/s13045-023-01487-5.CrossRefPubMedPubMedCentral

35.

Corzo CA, Cotter MJ, Cheng P, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009;182(9):5693–701. https://doi.org/10.4049/jimmunol.0900092.CrossRefPubMed

36.

Raber PL, Thevenot P, Sierra R, et al. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer. 2014;134(12):2853–64. https://doi.org/10.1002/ijc.28622.CrossRefPubMed

37.

Lu T, Ramakrishnan R, Altiok S, et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest. 2011;121(10):4015–29. https://doi.org/10.1172/JCI45862.CrossRefPubMedPubMedCentral

38.

Cartwright ANR, Suo S, Badrinath S, et al. Immunosuppressive myeloid cells induce nitric oxide-dependent DNA damage and p53 pathway activation in CD8(+) T Cells. Cancer Immunol Res. 2021;9(4):470–85. https://doi.org/10.1158/2326-6066.CIR-20-0085.CrossRefPubMedPubMedCentral

39.

Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008;222:180–91. https://doi.org/10.1111/j.1600-065X.2008.00608.x.CrossRefPubMedPubMedCentral

40.

Cimen Bozkus C, Elzey BD, Crist SA, et al. Expression of cationic amino acid transporter 2 is required for myeloid-derived suppressor cell-mediated control of T cell immunity. J Immunol. 2015;195(11):5237–50. https://doi.org/10.4049/jimmunol.1500959.CrossRefPubMed

41.

Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69(4):1553–60. https://doi.org/10.1158/0008-5472.CAN-08-1921.CrossRefPubMedPubMedCentral

42.

Zea AH, Rodriguez PC, Culotta KS, et al. L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol. 2004;232(1–2):21–31. https://doi.org/10.1016/j.cellimm.2005.01.004.CrossRefPubMed

43.

Srivastava MK, Sinha P, Clements VK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70(1):68–77. https://doi.org/10.1158/0008-5472.CAN-09-2587.CrossRefPubMed

44.

Yu J, Du W, Yan F, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190(7):3783–97. https://doi.org/10.4049/jimmunol.1201449.CrossRefPubMed

45.

Schafer CC, Wang Y, Hough KP, et al. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. Oncotarget. 2016;7(46):75407–24. https://doi.org/10.18632/oncotarget.12249.CrossRefPubMedPubMedCentral

46.

Liu Z, Yu X, Xu L, et al. Current insight into the regulation of PD-L1 in cancer. Exp Hematol Oncol. 2022;11(1):44. https://doi.org/10.1186/s40164-022-00297-8.CrossRefPubMedPubMedCentral

47.

Kim SH, Li M, Trousil S, et al. Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma. J Invest Dermatol. 2017;137(8):1740–8. https://doi.org/10.1016/j.jid.2017.03.033.CrossRefPubMed

48.

Wang L, Jia B, Claxton DF, et al. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. Oncoimmunology. 2018;7(9): e1469594. https://doi.org/10.1080/2162402X.2018.1469594.CrossRefPubMedPubMedCentral

49.

Deng J, Li J, Sarde A, et al. Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment. Cancer Immunol Res. 2019;7(7):1079–90. https://doi.org/10.1158/2326-6066.CIR-18-0507.CrossRefPubMedPubMedCentral

50.

Sakuishi K, Jayaraman P, Behar SM, et al. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011;32(8):345–9. https://doi.org/10.1016/j.it.2011.05.003.CrossRefPubMedPubMedCentral

51.

Zhang CX, Huang DJ, Baloche V, et al. Correction to: Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation. Oncogenesis. 2022;11(1):5. https://doi.org/10.1038/s41389-021-00375-2.CrossRefPubMedPubMedCentral

52.

Kong Y, Zhu L, Schell TD, et al. T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. Clin Cancer Res. 2016;22(12):3057–66. https://doi.org/10.1158/1078-0432.CCR-15-2626.CrossRefPubMed

53.

Wu L, Mao L, Liu JF, et al. Blockade of TIGIT/CD155 signaling reverses t-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma. Cancer Immunol Res. 2019;7(10):1700–13. https://doi.org/10.1158/2326-6066.CIR-18-0725.CrossRefPubMed

54.

Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–68. https://doi.org/10.1038/nri3175.CrossRefPubMedPubMedCentral

55.

Sinha P, Clements VK, Fulton AM, et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007;67(9):4507–13. https://doi.org/10.1158/0008-5472.CAN-06-4174.CrossRefPubMed

56.

Greifenberg V, Ribechini E, Rossner S, et al. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol. 2009;39(10):2865–76. https://doi.org/10.1002/eji.200939486.CrossRefPubMed

57.

Poschke I, Mao Y, Adamson L, et al. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother. 2012;61(6):827–38. https://doi.org/10.1007/s00262-011-1143-y.CrossRefPubMed

58.

Hu CE, Gan J, Zhang RD, et al. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol. 2011;46(2):156–64. https://doi.org/10.3109/00365521.2010.516450.CrossRefPubMed

59.

Ugolini A, Tyurin VA, Tyurina YY, et al. Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. JCI Insight. 2020. https://doi.org/10.1172/jci.insight.138581.CrossRefPubMedPubMedCentral

60.

Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182(1):240–9. https://doi.org/10.4049/jimmunol.182.1.240.CrossRefPubMed

61.

Di Pace AL, Tumino N, Besi F, et al. Characterization of Human NK Cell-Derived Exosomes: Role of DNAM1 Receptor In Exosome-Mediated Cytotoxicity Against Tumor. Cancers (Basel). 2020;12:3. https://doi.org/10.3390/cancers12030661.CrossRef

62.

Hoechst B, Voigtlaender T, Ormandy L, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology. 2009;50(3):799–807. https://doi.org/10.1002/hep.23054.CrossRefPubMed

63.

Vaknin I, Blinder L, Wang L, et al. A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression. Blood. 2008;111(3):1437–47. https://doi.org/10.1182/blood-2007-07-100404.CrossRefPubMed

64.

Zhang J, Han X, Hu X, et al. IDO1 impairs NK cell cytotoxicity by decreasing NKG2D/NKG2DLs via promoting miR-18a. Mol Immunol. 2018;103:144–55. https://doi.org/10.1016/j.molimm.2018.09.011.CrossRefPubMed

65.

Della Chiesa M, Carlomagno S, Frumento G, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood. 2006;108(13):4118–25. https://doi.org/10.1182/blood-2006-03-006700.CrossRefPubMed

66.

Sui Q, Zhang J, Sun X, et al. NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma. J Immunol. 2014;193(4):2016–23. https://doi.org/10.4049/jimmunol.1302389.CrossRefPubMed

67.

Tie Y, Tang F, Wei YQ, et al. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15(1):61. https://doi.org/10.1186/s13045-022-01282-8.CrossRefPubMedPubMedCentral

68.

Franklin RA, Liao W, Sarkar A, et al. The cellular and molecular origin of tumor-associated macrophages. Science. 2014;344(6186):921–5. https://doi.org/10.1126/science.1252510.CrossRefPubMedPubMedCentral

69.

Wang Y, Liu H, Zhang Z, et al. G-MDSC-derived exosomes mediate the differentiation of M-MDSC into M2 macrophages promoting colitis-to-cancer transition. J Immunother Cancer. 2023;11(6):45. https://doi.org/10.1136/jitc-2022-006166.CrossRef

70.

DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16(2):91–102. https://doi.org/10.1016/j.ccr.2009.06.018.CrossRefPubMedPubMedCentral

71.

Thibodeau J, Bourgeois-Daigneault MC, Huppe G, et al. Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. Eur J Immunol. 2008;38(5):1225–30. https://doi.org/10.1002/eji.200737902.CrossRefPubMedPubMedCentral

72.

Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66(2):1123–31. https://doi.org/10.1158/0008-5472.CAN-05-1299.CrossRefPubMed

73.

Serafini P, Mgebroff S, Noonan K, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68(13):5439–49. https://doi.org/10.1158/0008-5472.CAN-07-6621.CrossRefPubMedPubMedCentral

74.

Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2010;70(1):99–108. https://doi.org/10.1158/0008-5472.CAN-09-1882.CrossRefPubMed

75.

Schlecker E, Stojanovic A, Eisen C, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol. 2012;189(12):5602–11. https://doi.org/10.4049/jimmunol.1201018.CrossRefPubMed

76.

Fujimura T, Ring S, Umansky V, et al. Regulatory T cells stimulate B7–H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol. 2012;132(4):1239–46. https://doi.org/10.1038/jid.2011.416.CrossRefPubMed

77.

Yang X, Lin Y, Shi Y, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 2016;76(14):4124–35. https://doi.org/10.1158/0008-5472.CAN-15-2973.CrossRefPubMed

78.

Xiang H, Ramil CP, Hai J, et al. Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma. Cancer Immunol Res. 2020;8(4):436–50. https://doi.org/10.1158/2326-6066.CIR-19-0507.CrossRefPubMed

79.

Liang T, Tao T, Wu K, et al. Cancer-associated fibroblast-induced remodeling of tumor microenvironment in recurrent bladder cancer. Adv Sci (Weinh). 2023;10(31): e2303230. https://doi.org/10.1002/advs.202303230.CrossRefPubMed

80.

Deng Y, Cheng J, Fu B, et al. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells. Oncogene. 2017;36(8):1090–101. https://doi.org/10.1038/onc.2016.273.CrossRefPubMed

81.

Zhu GQ, Tang Z, Huang R, et al. CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 2023;9(1):25. https://doi.org/10.1038/s41421-023-00529-z.CrossRefPubMedPubMedCentral

82.

Zhao Q, Huang L, Qin G, et al. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. Cancer Lett. 2021;518:35–48. https://doi.org/10.1016/j.canlet.2021.06.009.CrossRefPubMed

83.

Lin Y, Cai Q, Chen Y, et al. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase. Hepatology. 2022;75(1):28–42. https://doi.org/10.1002/hep.32099.CrossRefPubMed

84.

Lideikaite A, Mozuraitiene J, Letautiene S. Analysis of prognostic factors for melanoma patients. Acta Med Litu. 2017;24(1):25–34. https://doi.org/10.6001/actamedica.v24i1.3460.CrossRefPubMedPubMedCentral

85.

Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol. 2011;104(4):341–53. https://doi.org/10.1002/jso.21962.CrossRefPubMed

86.

Jordan KR, Amaria RN, Ramirez O, et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother. 2013;62(11):1711–22. https://doi.org/10.1007/s00262-013-1475-x.CrossRefPubMedPubMedCentral

87.

Sade-Feldman M, Kanterman J, Klieger Y, et al. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. Clin Cancer Res. 2016;22(23):5661–72. https://doi.org/10.1158/1078-0432.CCR-15-3104.CrossRefPubMed

88.

Arkhypov I, Lasser S, Petrova V, et al. Myeloid cell modulation by tumor-derived extracellular vesicles. Int J Mol Sci. 2020;21(17):34. https://doi.org/10.3390/ijms21176319.CrossRef

89.

Arkhypov I, Ozbay Kurt FG, Bitsch R, et al. HSP90alpha induces immunosuppressive myeloid cells in melanoma via TLR4 signaling. J Immunother Cancer. 2022;10:9. https://doi.org/10.1136/jitc-2022-005551.CrossRef

90.

Tengesdal IW, Menon DR, Osborne DG, et al. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. Proc Natl Acad Sci U S A. 2021;118:10. https://doi.org/10.1073/pnas.2000915118.CrossRef

91.

Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13(6):397–411. https://doi.org/10.1038/nri3452.CrossRefPubMed

92.

Tengesdal IW, Dinarello A, Powers NE, et al. Tumor NLRP3-Derived IL-1beta Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression. Front Immunol. 2021;12: 661323. https://doi.org/10.3389/fimmu.2021.661323.CrossRefPubMedPubMedCentral

93.

Weber R, Riester Z, Huser L, et al. IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma. J Immunother Cancer. 2020;8:2. https://doi.org/10.1136/jitc-2020-000949.CrossRef

94.

Chang AL, Miska J, Wainwright DA, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory t cells and myeloid-derived suppressor cells. Cancer Res. 2016;76(19):5671–82. https://doi.org/10.1158/0008-5472.CAN-16-0144.CrossRefPubMedPubMedCentral

95.

Cheng Y, Ma XL, Wei YQ, et al. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochim Biophys Acta Rev Cancer. 2019;1871(2):289–312. https://doi.org/10.1016/j.bbcan.2019.01.005.CrossRefPubMed

96.

Groth C, Arpinati L, Shaul ME, et al. Blocking migration of polymorphonuclear myeloid-derived suppressor cells inhibits mouse melanoma progression. Cancers (Basel). 2021;13:4. https://doi.org/10.3390/cancers13040726.CrossRef

97.

Toh B, Wang X, Keeble J, et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011;9(9): e1001162. https://doi.org/10.1371/journal.pbio.1001162.CrossRefPubMedPubMedCentral

98.

Deng W, Fernandez A, McLaughlin SL, et al. Cell Communication Network Factor 4 (CCN4/WISP1) Shifts Melanoma Cells from a Fragile Proliferative State to a Resilient Metastatic State. Cell Mol Bioeng. 2020;13(1):45–60. https://doi.org/10.1007/s12195-019-00602-2.CrossRefPubMed

99.

Fernandez A, Deng W, McLaughlin SL, et al. Cell Communication Network factor 4 promotes tumor-induced immunosuppression in melanoma. EMBO Rep. 2022;23(4): e54127. https://doi.org/10.15252/embr.202154127.CrossRefPubMedPubMedCentral

100.

Theivanthiran B, Evans KS, DeVito NC, et al. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Invest. 2020;130(5):2570–86. https://doi.org/10.1172/JCI133055.CrossRefPubMedPubMedCentral

101.

Rawla P, Sunkara T, Muralidharan P, et al. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018;22(3):141–50. https://doi.org/10.5114/wo.2018.78941.CrossRefPubMed

102.

Li X, Xing YF, Lei AH, et al. Neutrophil count is associated with myeloid derived suppressor cell level and presents prognostic value of for hepatocellular carcinoma patients. Oncotarget. 2017;8(15):24380–8. https://doi.org/10.18632/oncotarget.15456.CrossRefPubMedPubMedCentral

103.

Zhou J, Liu M, Sun H, et al. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut. 2018;67(5):931–44. https://doi.org/10.1136/gutjnl-2017-314032.CrossRefPubMed

104.

Elwan N, Salem ML, Kobtan A, et al. High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cirrhotic and HCC patients. Immunol Invest. 2018;47(2):169–80. https://doi.org/10.1080/08820139.2017.1407787.CrossRefPubMed

105.

Zeng X, Liao G, Li S, et al. Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation. Hepatology. 2023;77(4):1122–38. https://doi.org/10.1002/hep.32585.CrossRefPubMed

106.

Simpson KD, Cross JV. MIF: metastasis/MDSC-inducing factor? Oncoimmunology. 2013;2(3): e23337. https://doi.org/10.4161/onci.23337.CrossRefPubMedPubMedCentral

107.

Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. https://doi.org/10.1016/j.cell.2012.03.042.CrossRefPubMedPubMedCentral

108.

Conche C, Finkelmeier F, Pesic M, et al. Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. Gut. 2023. https://doi.org/10.1136/gutjnl-2022-327909.CrossRefPubMed

109.

He Q, Liu M, Huang W, et al. IL-1beta-induced elevation of solute carrier family 7 member 11 promotes hepatocellular carcinoma metastasis through up-regulating programmed death ligand 1 and colony-stimulating factor 1. Hepatology. 2021;74(6):3174–93. https://doi.org/10.1002/hep.32062.CrossRefPubMed

110.

Wang W, Wu J, Ji M, et al. Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment. J Transl Med. 2020;18(1):477. https://doi.org/10.1186/s12967-020-02661-w.CrossRefPubMedPubMedCentral

111.

Xia S, Wu J, Zhou W, et al. SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. Cell Death Dis. 2021;12(6):570. https://doi.org/10.1038/s41419-021-03853-y.CrossRefPubMedPubMedCentral

112.

Li YM, Liu ZY, Wang JC, et al. Receptor-Interacting Protein Kinase 3 Deficiency Recruits Myeloid-Derived Suppressor Cells to Hepatocellular Carcinoma Through the Chemokine (C-X-C Motif) Ligand 1-Chemokine (C-X-C Motif) Receptor 2 Axis. Hepatology. 2019;70(5):1564–81. https://doi.org/10.1002/hep.30676.CrossRefPubMed

113.

Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal. 2007;9(8):1221–35. https://doi.org/10.1089/ars.2007.1628.CrossRefPubMed

114.

Chiu DK, Tse AP, Xu IM, et al. Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat Commun. 2017;8(1):517. https://doi.org/10.1038/s41467-017-00530-7.CrossRefPubMedPubMedCentral

115.

Raychaudhuri D, Bhattacharya R, Sinha BP, et al. Lactate induces pro-tumor reprogramming in intratumoral plasmacytoid dendritic cells. Front Immunol. 2019;10:1878. https://doi.org/10.3389/fimmu.2019.01878.CrossRefPubMedPubMedCentral

116.

Dias AS, Almeida CR, Helguero LA, et al. Metabolic crosstalk in the breast cancer microenvironment. Eur J Cancer. 2019;121:154–71. https://doi.org/10.1016/j.ejca.2019.09.002.CrossRefPubMed

117.

Wang N, Tan HY, Lu Y, et al. PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma. Signal Transduct Target Ther. 2021;6(1):86. https://doi.org/10.1038/s41392-021-00485-8.CrossRefPubMedPubMedCentral

118.

Awuah PK, Monga SP. Cell cycle-related kinase links androgen receptor and beta-catenin signaling in hepatocellular carcinoma: why are men at a loss? Hepatology. 2012;55(3):970–3. https://doi.org/10.1002/hep.24774.CrossRefPubMed

119.

Wang SH, Yeh SH, Chen PJ. The driving circuit of HBx and androgen receptor in HBV-related hepatocarcinogenesis. Gut. 2014;63(11):1688–9. https://doi.org/10.1136/gutjnl-2013-306678.CrossRefPubMed

120.

Feng H, Yu Z, Tian Y, et al. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients. J Hepatol. 2015;62(5):1100–11. https://doi.org/10.1016/j.jhep.2014.11.040.CrossRefPubMed

121.

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

122.

Miller LD, Chou JA, Black MA, et al. Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness. Cancer Immunol Res. 2016;4(7):600–10. https://doi.org/10.1158/2326-6066.CIR-15-0149.CrossRefPubMedPubMedCentral

123.

Alshetaiwi H, Pervolarakis N, McIntyre LL, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020;5:44. https://doi.org/10.1126/sciimmunol.aay6017.CrossRef

124.

Zhang R, Dong M, Tu J, et al. PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway. Signal Transduct Target Ther. 2023;8(1):97. https://doi.org/10.1038/s41392-023-01337-3.CrossRefPubMedPubMedCentral

125.

Peng D, Tanikawa T, Li W, et al. Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6/STAT3 and NO/NOTCH Cross-talk signaling. Cancer Res. 2016;76(11):3156–65. https://doi.org/10.1158/0008-5472.CAN-15-2528.CrossRefPubMedPubMedCentral

126.

Liu M, Wei F, Wang J, et al. Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1(-)PD-L1(+) Bregs through PD-L1/PI3K/AKT/NF-kappaB axis in breast cancer. Cell Death Dis. 2021;12(5):465. https://doi.org/10.1038/s41419-021-03745-1.CrossRefPubMedPubMedCentral

127.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

128.

Li W, Tanikawa T, Kryczek I, et al. Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. Cell Metab. 2018;28(1):87–103. https://doi.org/10.1016/j.cmet.2018.04.022.CrossRefPubMedPubMedCentral

129.

Xiao P, Wan X, Cui B, et al. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology. 2016;5(1): e1063772. https://doi.org/10.1080/2162402X.2015.1063772.CrossRefPubMed

130.

Trillo-Tinoco J, Sierra RA, Mohamed E, et al. AMPK Alpha-1 intrinsically regulates the function and differentiation of tumor myeloid-derived suppressor cells. Cancer Res. 2019;79(19):5034–47. https://doi.org/10.1158/0008-5472.CAN-19-0880.CrossRefPubMedPubMedCentral

131.

Jiang M, Zhang W, Zhang R, et al. Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer. Oncogene. 2020;39(24):4681–94. https://doi.org/10.1038/s41388-020-1322-4.CrossRefPubMed

132.

Yu B, Luo F, Sun B, et al. KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer. Adv Sci (Weinh). 2021;8(20): e2100014. https://doi.org/10.1002/advs.202100014.CrossRefPubMed

133.

Ruiz-Fernandez de Cordoba B, Moreno H, Valencia K, et al. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer. Cancer Discov. 2022;12(5):1356–1377.

134.

Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40–7. https://doi.org/10.1200/JCO.2016.69.1584.CrossRefPubMed

135.

Wang J, McGuire TR, Britton HC, et al. Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer. Clin Exp Metastasis. 2015;32(2):111–24. https://doi.org/10.1007/s10585-015-9696-3.CrossRefPubMed

136.

Lu X, Horner JW, Paul E, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543(7647):728–32. https://doi.org/10.1038/nature21676.CrossRefPubMedPubMedCentral

137.

Calcinotto A, Spataro C, Zagato E, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018;559(7714):363–9. https://doi.org/10.1038/s41586-018-0266-0.CrossRefPubMedPubMedCentral

138.

Burke M, Choksawangkarn W, Edwards N, et al. Exosomes from myeloid-derived suppressor cells carry biologically active proteins. J Proteome Res. 2014;13(2):836–43. https://doi.org/10.1021/pr400879c.CrossRefPubMed

139.

Gao F, Xu Q, Tang Z, et al. Exosomes derived from myeloid-derived suppressor cells facilitate castration-resistant prostate cancer progression via S100A9/circMID1/miR-506-3p/MID1. J Transl Med. 2022;20(1):346. https://doi.org/10.1186/s12967-022-03494-5.CrossRefPubMedPubMedCentral

140.

Hossain DM, Pal SK, Moreira D, et al. TLR9-Targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients. Clin Cancer Res. 2015;21(16):3771–82. https://doi.org/10.1158/1078-0432.CCR-14-3145.CrossRefPubMedPubMedCentral

141.

Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22. https://doi.org/10.1016/j.ccr.2010.05.026.CrossRefPubMedPubMedCentral

142.

Zhao D, Cai L, Lu X, et al. Chromatin regulator CHD1 remodels the immunosuppressive tumor microenvironment in PTEN-deficient prostate cancer. Cancer Discov. 2020;10(9):1374–87. https://doi.org/10.1158/2159-8290.CD-19-1352.CrossRefPubMedPubMedCentral

143.

Jachetti E, Rigoni A, Bongiovanni L, et al. Imatinib Spares cKit-expressing prostate neuroendocrine tumors, whereas kills seminal vesicle epithelial-stromal tumors by targeting PDGFR-beta. Mol Cancer Ther. 2017;16(2):365–75. https://doi.org/10.1158/1535-7163.MCT-16-0466.CrossRefPubMed

144.

Pittoni P, Tripodo C, Piconese S, et al. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res. 2011;71(18):5987–97. https://doi.org/10.1158/0008-5472.CAN-11-1637.CrossRefPubMed

145.

Jachetti E, Cancila V, Rigoni A, et al. Cross-talk between myeloid-derived suppressor cells and mast cells mediates tumor-specific immunosuppression in prostate cancer. Cancer Immunol Res. 2018;6(5):552–65. https://doi.org/10.1158/2326-6066.CIR-17-0385.CrossRefPubMed

146.

Miret JJ, Kirschmeier P, Koyama S, et al. Suppression of myeloid cell arginase activity leads to therapeutic response in a NSCLC mouse model by activating anti-tumor immunity. J Immunother Cancer. 2019;7(1):32. https://doi.org/10.1186/s40425-019-0504-5.CrossRefPubMedPubMedCentral

147.

Wang Y, Schafer CC, Hough KP, et al. Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5. J Immunol. 2018;201(1):278–95. https://doi.org/10.4049/jimmunol.1701069.CrossRefPubMed

148.

Lee JK, Won C, Yi EH, et al. Signal transducer and activator of transcription 3 (Stat3) contributes to T-cell homeostasis by regulating pro-survival Bcl-2 family genes. Immunology. 2013;140(3):288–300. https://doi.org/10.1111/imm.12133.CrossRefPubMedPubMedCentral

149.

Li Y, Du H, Qin Y, et al. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res. 2007;67(18):8494–503. https://doi.org/10.1158/0008-5472.CAN-07-0647.CrossRefPubMed

150.

Tao Q, Fujimoto J, Men T, et al. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst. 2007;99(22):1668–82. https://doi.org/10.1093/jnci/djm208.CrossRefPubMed

151.

Zhong S, Yin H, Liao Y, et al. Lung Tumor Suppressor GPRC5A Binds EGFR and Restrains Its Effector Signaling. Cancer Res. 2015;75(9):1801–14. https://doi.org/10.1158/0008-5472.CAN-14-2005.CrossRefPubMed

152.

Jing B, Wang T, Sun B, et al. IL6/STAT3 signaling orchestrates premetastatic niche formation and immunosuppressive traits in lung. Cancer Res. 2020;80(4):784–97. https://doi.org/10.1158/0008-5472.CAN-19-2013.CrossRefPubMed

153.

Wang T, Jing B, Xu D, et al. PTGES/PGE(2) signaling links immunosuppression and lung metastasis in Gprc5a-knockout mouse model. Oncogene. 2020;39(15):3179–94. https://doi.org/10.1038/s41388-020-1207-6.CrossRefPubMedPubMedCentral

154.

Liu NN, Yi CX, Wei LQ, et al. The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells. Cancer Cell. 2023;41(11):1927–44. https://doi.org/10.1016/j.ccell.2023.08.012.CrossRefPubMed

155.

Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19(9):495–509. https://doi.org/10.1038/s41568-019-0179-8.CrossRefPubMedPubMedCentral

156.

Koyama S, Akbay EA, Li YY, et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 2016;76(5):999–1008. https://doi.org/10.1158/0008-5472.CAN-15-1439.CrossRefPubMedPubMedCentral

157.

Li R, Salehi-Rad R, Crosson W, et al. Inhibition of granulocytic myeloid-derived suppressor cells overcomes resistance to immune checkpoint inhibition in LKB1-deficient non-small cell lung cancer. Cancer Res. 2021;81(12):3295–308. https://doi.org/10.1158/0008-5472.CAN-20-3564.CrossRefPubMedPubMedCentral

158.

Li Y, Qu P, Wu L, et al. Api6/AIM/Spalpha/CD5L overexpression in alveolar type II epithelial cells induces spontaneous lung adenocarcinoma. Cancer Res. 2011;71(16):5488–99. https://doi.org/10.1158/0008-5472.CAN-10-4225.CrossRefPubMedPubMedCentral

159.

Zhao S, Guo T, Li J, et al. Expression and prognostic value of GalNAc-T3 in patients with completely resected small (</=2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification. Onco Targets Ther. 2015;8:3143–52. https://doi.org/10.2147/OTT.S93486.CrossRefPubMedPubMedCentral

160.

Park MS, Yang AY, Lee JE, et al. GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner. Cancer Lett. 2021;521:294–307. https://doi.org/10.1016/j.canlet.2021.08.015.CrossRefPubMed

161.

Zhao T, Liu S, Hanna NH, et al. LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer. J Immunother Cancer. 2023;11(3): e006272. https://doi.org/10.1136/jitc-2022-006272.CrossRefPubMedPubMedCentral

162.

Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–98. https://doi.org/10.1038/nrc.2016.73.CrossRefPubMed

163.

Porembka MR, Mitchem JB, Belt BA, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. 2012;61(9):1373–85. https://doi.org/10.1007/s00262-011-1178-0.CrossRefPubMedPubMedCentral

164.

Zhang J, Xu X, Shi M, et al. CD13(hi) Neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma. Oncoimmunology. 2017;6(2): e1258504. https://doi.org/10.1080/2162402X.2016.1258504.CrossRefPubMedPubMedCentral

165.

Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67(19):9518–27. https://doi.org/10.1158/0008-5472.CAN-07-0175.CrossRefPubMed

166.

Stromnes IM, Brockenbrough JS, Izeradjene K, et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut. 2014;63(11):1769–81. https://doi.org/10.1136/gutjnl-2013-306271.CrossRefPubMed

167.

Choueiry F, Torok M, Shakya R, et al. CD200 promotes immunosuppression in the pancreatic tumor microenvironment. J Immunother Cancer. 2020;8(1):10. https://doi.org/10.1136/jitc-2019-000189.CrossRef

168.

Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63(5):318–48. https://doi.org/10.3322/caac.21190.CrossRefPubMedPubMedCentral

169.

Yang X, Lu Y, Hang J, et al. Lactate-modulated immunosuppression of myeloid-derived suppressor cells contributes to the radioresistance of pancreatic cancer. Cancer Immunol Res. 2020;8(11):1440–51. https://doi.org/10.1158/2326-6066.CIR-20-0111.CrossRefPubMed

170.

Chun E, Lavoie S, Michaud M, et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep. 2015;12(2):244–57. https://doi.org/10.1016/j.celrep.2015.06.024.CrossRefPubMedPubMedCentral

171.

Maisonneuve C, Tsang DKL, Foerster EG, et al. Nod1 promotes colorectal carcinogenesis by regulating the immunosuppressive functions of tumor-infiltrating myeloid cells. Cell Rep. 2021;34(4): 108677. https://doi.org/10.1016/j.celrep.2020.108677.CrossRefPubMed

172.

Wang Y, Yin K, Tian J, et al. Granulocytic myeloid-derived suppressor cells promote the stemness of colorectal cancer cells through exosomal S100A9. Adv Sci (Weinh). 2019;6(18):1901278. https://doi.org/10.1002/advs.201901278.CrossRefPubMed

173.

Chen H, Pan Y, Zhou Q, et al. METTL3 Inhibits Antitumor Immunity by Targeting m(6)A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer. Gastroenterology. 2022;163(4):891–907. https://doi.org/10.1053/j.gastro.2022.06.024.CrossRefPubMed

174.

Du Z, Su J, Lin S, et al. Hydroxyphenylpyruvate Dioxygenase Is a Metabolic Immune Checkpoint for UTX-deficient Colorectal Cancer. Gastroenterology. 2023;164(7):1165–79. https://doi.org/10.1053/j.gastro.2023.02.010.CrossRefPubMed

175.

Zhang Z, Zheng Y, Chen Y, et al. Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis. Exp Hematol Oncol. 2022;11(1):88. https://doi.org/10.1186/s40164-022-00334-6.CrossRefPubMedPubMedCentral

176.

Yu S, Ren X, Li L. Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin. Exp Hematol Oncol. 2022;11(1):43. https://doi.org/10.1186/s40164-022-00296-9.CrossRefPubMedPubMedCentral

177.

Jitschin R, Saul D, Braun M, et al. CD33/CD3-bispecific T-cell engaging (BiTE(R)) antibody construct targets monocytic AML myeloid-derived suppressor cells. J Immunother Cancer. 2018;6(1):116. https://doi.org/10.1186/s40425-018-0432-9.CrossRefPubMedPubMedCentral

178.

Tohumeken S, Baur R, Bottcher M, et al. Palmitoylated proteins on AML-derived extracellular vesicles promote myeloid-derived suppressor cell differentiation via TLR2/Akt/mTOR Signaling. Cancer Res. 2020;80(17):3663–76. https://doi.org/10.1158/0008-5472.CAN-20-0024.CrossRefPubMed

179.

Cai B, Liu Y, Chong Y, et al. IRAK1-regulated IFN-gamma signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies. Mol Cancer. 2021;20(1):165. https://doi.org/10.1186/s12943-021-01460-1.CrossRefPubMedPubMedCentral

180.

Highfill SL, Cui Y, Giles AJ, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6(237):237–67. https://doi.org/10.1126/scitranslmed.3007974.CrossRef

181.

Raychaudhuri B, Rayman P, Ireland J, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011;13(6):591–9. https://doi.org/10.1093/neuonc/nor042.CrossRefPubMedPubMedCentral

182.

Gieryng A, Pszczolkowska D, Walentynowicz KA, et al. Immune microenvironment of gliomas. Lab Invest. 2017;97(5):498–518. https://doi.org/10.1038/labinvest.2017.19.CrossRefPubMed

183.

Su MT, Kumata S, Endo S, et al. LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs. Oncoimmunology. 2022;11(1):2060907. https://doi.org/10.1080/2162402X.2022.2060907.CrossRefPubMedPubMedCentral

184.

Cheng X, Wang H, Wang Z, et al. Tumor-associated myeloid cells in cancer immunotherapy. J Hematol Oncol. 2023;16(1):71. https://doi.org/10.1186/s13045-023-01473-x.CrossRefPubMedPubMedCentral

185.

Wang Y, Johnson KCC, Gatti-Mays ME, et al. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. J Hematol Oncol. 2022;15(1):118. https://doi.org/10.1186/s13045-022-01335-y.CrossRefPubMedPubMedCentral

186.

Bronte V, Serafini P, Apolloni E, et al. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother. 2001;24(6):431–46. https://doi.org/10.1097/00002371-200111000-00001.CrossRefPubMed

187.

Zheng Y, Xu M, Li X, et al. Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol. 2013;54(1):74–83. https://doi.org/10.1016/j.molimm.2012.10.035.CrossRefPubMed

188.

Condamine T, Kumar V, Ramachandran IR, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest. 2014;124(6):2626–39. https://doi.org/10.1172/JCI74056.CrossRefPubMedPubMedCentral

189.

Svoronos N, Perales-Puchalt A, Allegrezza MJ, et al. Tumor cell-independent estrogen signaling drives disease progression through mobilization of myeloid-derived suppressor cells. Cancer Discov. 2017;7(1):72–85. https://doi.org/10.1158/2159-8290.CD-16-0502.CrossRefPubMed

190.

Liu M, Zhou J, Liu X, et al. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut. 2020;69(2):365–79. https://doi.org/10.1136/gutjnl-2018-317257.CrossRefPubMed

191.

Tavazoie MF, Pollack I, Tanqueco R, et al. LXR/ApoE activation restricts innate immune suppression in cancer. Cell. 2018;172(4):825–40. https://doi.org/10.1016/j.cell.2017.12.026.CrossRefPubMedPubMedCentral

192.

Welters MJ, van der Sluis TC, van Meir H, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med. 2016;8(334):334–52. https://doi.org/10.1126/scitranslmed.aad8307.CrossRef

193.

Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol. 2002;2(3):175–84. https://doi.org/10.1038/nri748.CrossRefPubMed

194.

Fedele C, Li S, Teng KW, et al. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. J Exp Med. 2021. https://doi.org/10.1084/jem.20201414.CrossRefPubMed

195.

Quintana E, Schulze CJ, Myers DR, et al. Allosteric Inhibition of SHP2 stimulates antitumor immunity by transforming the immunosuppressive environment. Cancer Res. 2020;80(13):2889–902. https://doi.org/10.1158/0008-5472.CAN-19-3038.CrossRefPubMed

196.

Tang KH, Li S, Khodadadi-Jamayran A, et al. Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. Cancer Discov. 2022;12(1):47–61. https://doi.org/10.1158/2159-8290.CD-21-0369.CrossRefPubMed

197.

Lu Z, Zou J, Li S, et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020;579(7798):284–90. https://doi.org/10.1038/s41586-020-2054-x.CrossRefPubMedPubMedCentral

198.

Sun L, Clavijo PE, Robbins Y, et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 2019;4:7. https://doi.org/10.1172/jci.insight.126853.CrossRef

199.

Tap WD, Wainberg ZA, Anthony SP, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428–37. https://doi.org/10.1056/NEJMoa1411366.CrossRefPubMed

200.

Cannarile MA, Weisser M, Jacob W, et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5(1):53. https://doi.org/10.1186/s40425-017-0257-y.CrossRefPubMedPubMedCentral

201.

Mok S, Koya RC, Tsui C, et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014;74(1):153–61. https://doi.org/10.1158/0008-5472.CAN-13-1816.CrossRefPubMed

202.

Zhu Y, Yang J, Xu D, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019;68(9):1653–66. https://doi.org/10.1136/gutjnl-2019-318419.CrossRefPubMed

203.

Kumar V, Donthireddy L, Marvel D, et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell. 2017;32(5):654–68. https://doi.org/10.1016/j.ccell.2017.10.005.CrossRefPubMedPubMedCentral

204.

Nywening TM, Belt BA, Cullinan DR, et al. Targeting both tumour-associated CXCR2(+) neutrophils and CCR2(+) macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut. 2018;67(6):1112–23. https://doi.org/10.1136/gutjnl-2017-313738.CrossRefPubMed

205.

Hasnis E, Alishekevitz D, Gingis-Veltski S, et al. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy. Neoplasia. 2014;16(6):501–10. https://doi.org/10.1016/j.neo.2014.05.011.CrossRefPubMedPubMedCentral

206.

Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203(12):2691–702. https://doi.org/10.1084/jem.20061104.CrossRefPubMedPubMedCentral

207.

Lin S, Wang J, Wang L, et al. Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC. Am J Cancer Res. 2017;7(1):41–52.PubMedPubMedCentral

208.

Yu SJ, Ma C, Heinrich B, et al. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. J Hepatol. 2019;70(3):449–57. https://doi.org/10.1016/j.jhep.2018.10.040.CrossRefPubMed

209.

Benguigui M, Vorontsova A, Timaner M, et al. Bv8 blockade sensitizes Anti-PD1 therapy resistant tumors. Front Immunol. 2022;13: 903591. https://doi.org/10.3389/fimmu.2022.903591.CrossRefPubMedPubMedCentral

210.

Sturgill ER, Rolig AS, Linch SN, et al. Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity. Oncoimmunology. 2021;10(1):1892265. https://doi.org/10.1080/2162402X.2021.1892265.CrossRefPubMedPubMedCentral

211.

Alvear-Arias JJ, Carrillo C, Villar JP, et al. Expression of H(v)1 proton channels in myeloid-derived suppressor cells (MDSC) and its potential role in T cell regulation. Proc Natl Acad Sci U S A. 2022;119(15): e2104453119. https://doi.org/10.1073/pnas.2104453119.CrossRefPubMedPubMedCentral

212.

Ishfaq M, Pham T, Beaman C, et al. BTK inhibition reverses MDSC-mediated immunosuppression and enhances response to Anti-PDL1 therapy in neuroblastoma. Cancers (Basel). 2021;13(4):817. https://doi.org/10.3390/cancers13040817.CrossRefPubMed

213.

Weed DT, Vella JL, Reis IM, et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21(1):39–48. https://doi.org/10.1158/1078-0432.CCR-14-1711.CrossRefPubMed

214.

Noonan KA, Ghosh N, Rudraraju L, et al. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. Cancer Immunol Res. 2014;2(8):725–31. https://doi.org/10.1158/2326-6066.CIR-13-0213.CrossRefPubMedPubMedCentral

215.

Van Wigcheren GF, De Haas N, Mulder TA, et al. Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients. Oncoimmunology. 2021;10(1):1935557. https://doi.org/10.1080/2162402X.2021.1935557.CrossRefPubMedPubMedCentral

216.

Yan D, Wang HW, Bowman RL, et al. STAT3 and STAT6 signaling pathways synergize to promote cathepsin secretion from macrophages via IRE1alpha activation. Cell Rep. 2016;16(11):2914–27. https://doi.org/10.1016/j.celrep.2016.08.035.CrossRefPubMedPubMedCentral

217.

Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, et al. ER Stress Sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell. 2015;161(7):1527–38. https://doi.org/10.1016/j.cell.2015.05.025.CrossRefPubMedPubMedCentral

218.

Mohamed E, Sierra RA, Trillo-Tinoco J, et al. The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity. 2020;52(4):668–82. https://doi.org/10.1016/j.immuni.2020.03.004.CrossRefPubMedPubMedCentral

219.

Gabrilovich DI, Velders MP, Sotomayor EM, et al. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001;166(9):5398–406. https://doi.org/10.4049/jimmunol.166.9.5398.CrossRefPubMed

220.

Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003;63(15):4441–9.PubMed

221.

Nefedova Y, Fishman M, Sherman S, et al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007;67(22):11021–8. https://doi.org/10.1158/0008-5472.CAN-07-2593.CrossRefPubMed

222.

Bauer R, Udonta F, Wroblewski M, et al. Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of antiangiogenic therapy. Cancer Res. 2018;78(12):3220–32. https://doi.org/10.1158/0008-5472.CAN-17-3415.CrossRefPubMed

223.

He Y, Hung SW, Liang B, et al. Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis. Front Immunol. 2021;12: 641206. https://doi.org/10.3389/fimmu.2021.641206.CrossRefPubMedPubMedCentral

224.

Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006;66(18):9299–307. https://doi.org/10.1158/0008-5472.CAN-06-1690.CrossRefPubMedPubMedCentral

225.

Li MO, Wolf N, Raulet DH, et al. Innate immune cells in the tumor microenvironment. Cancer Cell. 2021;39(6):725–9. https://doi.org/10.1016/j.ccell.2021.05.016.CrossRefPubMed

Title: Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion
Authors: Junli Lu
Yiming Luo
Dean Rao
Tiantian Wang
Zhen Lei
Xiaoping Chen
Bixiang Zhang
Yiwei Li
Bifeng Liu
Limin Xia
Wenjie Huang
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Experimental Hematology & Oncology / Issue 1/2024
Electronic ISSN: 2162-3619
DOI: https://doi.org/10.1186/s40164-024-00505-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases

Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies

Suppression of A-to-I RNA-editing enzyme ADAR1 sensitizes hepatocellular carcinoma cells to oxidative stress through regulating Keap1/Nrf2 pathway

Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects

The roles of tissue resident macrophages in health and cancer

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting

Keynote webinar | Spotlight on antibody–drug conjugates in cancer